| Therapeutic | Tebotelimab |
| Target 1 | PDCD1/CD279/PD1 |
| Heavy Chain 1 | QVQLVQSGAEVKKPGASVKVSCKASGYSFTSYWMNWVRQAPGQGLEWIGVIHPSDSETWLDQKFKDRVTITVDKSTSTAYMELSSLRSEDTAVYYCAREHYGTSPFAYWGQGTLVTVSS |
| Light Chain 1 | EIVLTQSPATLSLSPGERATLSCRASESVDNYGMSFMNWFQQKPGQPPKLLIHAASNQGSGVPSRFSGSGSGTDFTLTISSLEPEDFAVYFCQQSKEVPYTFGGGTKVEIK |
| 100% seqID Fv 1 Structure | None |
| 99% seqID Fv 1 Structure | None |
| 95-98% seqID Fv 1 Structure | None |
| Target 2 | LAG3/CD223 |
| Heavy Chain 2 | QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYNMDWVRQAPGQGLEWMGDINPDNGVTIYNQKFEGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCAREADYFYFDYWGQGTTLTVSS |
| Light Chain 2 | DIQMTQSPSSLSASVGDRVTITCRASQDVSSVVAWYQQKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQHYSTPWTFGGGTKLEIK |
| 100% seqID Fv 2 Structure | None |
| 99% seqID Fv 2 Structure | None |
| 95-98% seqID Fv 2 Structure | None |
Follow these links to our prediction tools:
| Format | Bispecific scFv with Crossover |
| Isotype | G4;G4 |
| Highest Clinical Trial (Feb '25) | Phase-II/III |
| Estimated Status (Feb '25) | Discontinued |
| Recorded Developmental Technology | |
| INN Year Proposed | 2019 |
| INN Year Recommended | 2020 |
| Companies Involved | MacroGenics |
| Conditions Approved | na |
| Conditions Active | na |
| Conditions Discontinued | Biliary cancer, Cholangiocarcinoma, Endometrial cancer, Gastric cancer, Haematological malignancies, Head and neck cancer, Liver cancer, Malignant melanoma, Oesophageal cancer, Solid tumours, Triple negative breast cancer |
| Notes |
Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]
SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]
Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]
